2019 was another big year for novel drug approvals (48 in total) though it wasn’t the record year of 2018 (with 59). The overall explosion in biologic drugs / non-small molecule modalities continued with year with 14 novel biologic drugs, including 3 monoclonal antibodies, a recombinant fusion protein (Reblozyl), 3 ADCs, an siRNA drug (Givlaari), an antisense oligonucleotide (Vyondys 53), a nanobody (Cablivi) and a single-chain antibody (Beovu). Here’s a visual summary of the 14 biologics approved in 2019.1 Happy 2020!

*Note: this SVG image sometimes displays improperly on mobile devices and is best viewed on a desktop browser or as a PDF.

To subscribe and download the poster in PDF format, click below:

2019 Biologic Drug Approvals

SUBSCRIBE & DOWNLOAD

send download link to:

I confirm that I have read and agree to the Terms of Use and Privacy Policy.

For a graphic of 2019 small molecule drugs, see this previous post. To compare these statistics to last year, see this previous post.

Explore drughunter.com for more.

  1. This doesn’t include biologic agents like vaccines or gene therapies like Zolgensma, covered under the FDA’s Biologic License Application Approvals.